At least 20% of women with ovarian cancer have a genetic predisposition to the disease even if they don’t have a family history ovarian cancer, according to a recent study. … Continued
(January 22, 2014) Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and … Continued
(January 13, 2014) Researchers at Case Western Reserve University, led by OCRFA grantee Analisa DiFeo, PhD have identified a microRNA biomarker that shows promise in predicting treatment response in the … Continued
Kicks off 20th Anniversary with an unprecedented grant award for scientific research and gynecologic cancer patient support program New York, NY January 13, 2014 — To mark its 20th anniversary, … Continued
OCRF has awarded $6.5 million in research grants to 22 scientists at leading medical institutions across the country.
A new combination therapy developed by researchers at the Roswell Park Cancer Institute has showed positive results in 60% of women with recurrent ovarian cancer. To develop the new therapy, … Continued
New research funded by OCRF shows that treatment with the drug decitabine, prior to administration of chemotherapy and a cancer vaccine, yielded clinical benefit for women with recurrent ovarian cancer. … Continued
(December 30, 2013) The U.S. Preventive Services Task Force (Task Force) has issued a final recommendation statement on Risk Assessment, Genetic Counseling, and Genetic Testing for BRCA-related Cancer in Women. … Continued
(December 20, 2013) Researchers have found that for women with advanced-stage ovarian cancer, being treated at a high volume hospital with a high volume provider, leads to improved survival. The … Continued
A targeted drug delivery system developed at Rutgers University could possibly make ovarian cancer more treatable. The study results published in Clinical Cancer Research also indicated the new system could increase survival … Continued
Research funded by Ovarian Cancer Research Fund shows that adipose derived stromal cells derived from the human omentum can promote ovarian cancer proliferation, migration, chemoresistance and radiation resistance in-vitro. The research, … Continued
A team of current and former OCRF grantees at Brigham and Women’s Hospital, Harvard Medical School and Dana-Farber Cancer Institute has developed genetically engineered mouse models of high-grade serous ovarian cancer that … Continued
Get email updates about research news, action alerts, and ways to join the fight.
